Glucagon-like peptide-1 (GLP-1) is an incretin peptide hormone mainly secreted by enteroendocrine intestinal L-cells. GLP-1 is also secreted by α-cells of the pancreas and the central nervous system (CNS). GLP-1 secretion is stimulated by nutrient intake and exerts its effects on glucose h...
Here's a breakdown of the currently available GLP-1 medication options and examples:Short-Acting Injectable GLP-1 DrugsGLP-1 agonist drugs that are dosed once or twice a day are considered short-acting formulations. These GLP-1 RA medications are typically administered via subcutaneous injection, ...
However, not all the GLP-1 Ra are equal when looking at cardioprotection. Lixisenatide, a short acting GLP1Ra failed to demonstrate CV benefits, while liraglutide, semaglutide, dulaglutide and efpeglenatide demonstrated to lower CV events [116]. Reduced mortality was also noted with liraglutide, ...
This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks. 显示全部 2025-04-01·CURRENT PROBLEMS IN CARDIOLOGY Real...
BackgroundHigh prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristic...
While much work has been performed in heterologous cell systems expressing GLP1R and GIPR, we will use examples pertinent to primary tissues wherever possible to increase relevance for islet biology. 2. GLP1R expression patterns Table 1 summarizes GLP1R expression patterns and levels in the islet....
Here, we present three cases of severe diarrhoea secondary to extensive ileal resection in which the use of the GLP-1 RA, liraglutide, was well tolerated and resulted in an objective improvement in diarrhoeal symptoms. We further provide a narrative review of the emerging evidence base supporting...
Examples of GLP-1 receptor agonist compounds are derived from human GLP-1 (7-37), exendin-4(1-39), or GLP-1 A (1-37). The invention also relates to derivatives of these compounds, in particular compounds with one or more ... JT Kodra,J Madsen,PW Garibay - US 被引量: 3发表: ...
This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks. 显示全部 2025-03-01·Metabolism Effect of glucagon-like ...
1: Y—Z—P, wherein P represents a fragment of a GLP-1 receptor agonist peptide lacking the two N-terminal amino acid residues; and Y—Z represents novel His-Ala mimetics. Examples of GLP-1 receptor agonist compounds are derived from human GLP-1 (7-37), exendin-4(1-39), or GLP-...